Skin Cancer

The addition of bemcentinib to the standard-of-care therapies of pembrolizumab or dabrafenib plus trametinib was well tolerated in patients with metastatic melanoma; however, it did not lead to improvements in overall response rate, progression-free survival, or overall survival vs SOC alone.

Each of 3 patients treated with cemiplimab achieved a near complete response.

Identifying social determinants in TEM is crucial to eliminating disparities in care, study authors wrote.

Immunotherapies, including PD-1 checkpoint inhibitors such as nivolumab, have improved the treatment options for patients with advanced melanoma.

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.

Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.

Click here to answer this week's skin cancer poll.

ChatGPT shows promise in dermatology but needs improvement in accuracy and conciseness for reliable clinical use, according to a study evaluating its performance in actinic keratosis management.

A poster presented at SDPA’s fall conference revealed key insights into the importance of close monitoring and preventative measures in patients with cSCC.

Orit Markowitz, MD, discusses pearls her SDPA fall conference sessions, "Melanoma Diagnosis, Outcomes and Survival," and "Advanced Conditions."

The goal of Arron et al’s study was to determine if the 40-GEP test could identify high-risk cSCC patients who would benefit from ART in controlling metastatic disease progression.

Farberg is looking forward to another year of top-notch presentations at Fall Clinical 2023.

The advancement is based on previous observations of preliminary clinical efficacy. There are currently no FDA-approved therapies for this patient population.

Approval is based on data from Bristol Myers Squibb’s CheckMate – 76K trial.

Aaron Farberg, MD, and Shanna Miranti, MPAS, PA-C, discuss the upcoming approvals of nivolumab and IDP-126.

Greater treatment costs are associated with more advanced stages of melanoma, particularly due to increasing prices of treatments.

Click here to answer this week's skin cancer poll.

Surgical removal techniques including Mohs surgery and excisional surgery are preferred treatment approach when addressing BCCs, particularly on the hands.

Dermatologist Laura Ferris, MD, PhD, discusses skin-related toxicities as a result of immunotherapies for the treatment and management of cancers.

Many studies have investigated the associations between lichen sclerosus and vulvar and penile SCCs, as well as genital melanomas.

In this week’s Pointers With Portela, the 208SkinDoc explains why individuals with certain careers have an increased risk of developing skin cancer.

Learn more about the in-depth topics covered in the September 2023 Frontline Forum BCC management supplement of Dermatology Times.

In the final part of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, review 4 real-world clinical cases of BCC and the treatments they utilized.

In part 3 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

Frequent fliers, including pilots and cabin crew, are exposed to greater levels of UV and cosmic ionizing radiation than the general population, leading to higher incidence of skin cancers.

In part 2 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

In part 1 of this Frontline Forum series, Brent Moody, MD; Sarah Arron, MD, PhD; Justine Cohen, DO; Emily Ruiz, MD, MPH; and Todd Schlesinger, MD, discuss non-surgical treatment options for the management of BCC, dose adjustments for systemic treatments, combining hedgehog pathway inhibitors with immunotherapy, and more.

Rescue workers had a higher rate of malignant melanoma between 2005 and 2015 compared the general population of New York State.

Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.

A coprimary end point in the phase 3 LEAP-010 study will not be met.